150 related articles for article (PubMed ID: 25526554)
1. Author's response to RE: Testosterone treatment is a potent tumor promoter for the rat prostate.
Bosland MC
Endocrinology; 2015 Jan; 156(1):L3-4. PubMed ID: 25526554
[No Abstract] [Full Text] [Related]
2. RE: Testosterone treatment is a potent tumor promoter for the rat prostate.
Traish AM; Morgentaler A; Khera M
Endocrinology; 2015 Jan; 156(1):L1-2. PubMed ID: 25526553
[No Abstract] [Full Text] [Related]
3. Words of wisdom. Re: Testosterone treatment is a potent tumor promoter for the rat prostate.
Scovell JM; Butler P; Ramasamy R; Lamb DJ
Eur Urol; 2015 Apr; 67(4):814-5. PubMed ID: 25765210
[No Abstract] [Full Text] [Related]
4. Testosterone treatment is a potent tumor promoter for the rat prostate.
Bosland MC
Endocrinology; 2014 Dec; 155(12):4629-33. PubMed ID: 25247471
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
Halland A; Jønler M; Pedersen KV
Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
[TBL] [Abstract][Full Text] [Related]
6. Malignant medication? Testosterone and cancer.
Pastuszak AW
BJU Int; 2015 Feb; 115(2):179-80. PubMed ID: 25604717
[No Abstract] [Full Text] [Related]
7. Testosterone therapy and prostate cancer--safety concerns are well founded.
Klotz L
Nat Rev Urol; 2015 Jan; 12(1):48-54. PubMed ID: 25563848
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer risk in testosterone-treated men.
Raynaud JP
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
[TBL] [Abstract][Full Text] [Related]
9. Will I have a heart attack or stroke if I take testosterone therapy?
Morgentaler A
J Sex Med; 2014 Jun; 11(6):1601-2. PubMed ID: 24905250
[No Abstract] [Full Text] [Related]
10. Re: Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
Taneja SS
J Urol; 2013 Oct; 190(4):1246. PubMed ID: 24029310
[No Abstract] [Full Text] [Related]
11. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer in men using testosterone supplementation.
Gaylis FD; Lin DW; Ignatoff JM; Amling CL; Tutrone RF; Cosgrove DJ
J Urol; 2005 Aug; 174(2):534-8; discussion 538. PubMed ID: 16006887
[TBL] [Abstract][Full Text] [Related]
13. Testosterone may speed up the growth of prostate cancer due to aromatase activity.
Friedman AE
BJU Int; 2010 Aug; 106(3):434. PubMed ID: 20653657
[No Abstract] [Full Text] [Related]
14. Haematological actions of androgens.
Warren AM; Grossmann M
Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101653. PubMed ID: 35414435
[TBL] [Abstract][Full Text] [Related]
15. Notice of duplicate publication: "Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis" (arch intern med. 2008;168[2]:235-236).
Shariat SF; Roehrborn CG; Lamb DJ; Slawin KM
Arch Intern Med; 2008 Oct; 168(18):2046-7. PubMed ID: 18852410
[No Abstract] [Full Text] [Related]
16. Testosterone therapy in the ageing male: what about the prostate?
Schultheiss D; Machtens S; Jonas U
Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
[TBL] [Abstract][Full Text] [Related]
17. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study.
Wallis CJ; Lo K; Lee Y; Krakowsky Y; Garbens A; Satkunasivam R; Herschorn S; Kodama RT; Cheung P; Narod SA; Nam RK
Lancet Diabetes Endocrinol; 2016 Jun; 4(6):498-506. PubMed ID: 27165609
[TBL] [Abstract][Full Text] [Related]
18. Induction of prostatic carcinomas and lower urinary tract neoplasms by combined treatment of intact and castrated rats with testosterone propionate and N-nitrosobis(2-oxopropyl)amine.
Pour PM; Stepan K
Cancer Res; 1987 Nov; 47(21):5699-706. PubMed ID: 3664475
[TBL] [Abstract][Full Text] [Related]
19. [Testosterone and the prostate].
Wirth MP; Hakenberg OW
Urologe A; 2000 Sep; 39(5):418-20. PubMed ID: 11045041
[TBL] [Abstract][Full Text] [Related]
20. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer.
Meza J; Weaver K; Martin S
Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582
[No Abstract] [Full Text] [Related]
[Next] [New Search]
